目的 探討重組腺病毒相關(guān)病毒(rAAV)的制備以及作為肝癌基因治療載體的可行性。
方法 重組報告基因加強(qiáng)的綠色熒光蛋白(EGFP)基因至質(zhì)粒載體pSub201,用雙質(zhì)粒共轉(zhuǎn)染方法制備重組腺病毒相關(guān)病毒顆粒(rAAV/EGFP),觀察其對肝癌細(xì)胞系的感染性。
結(jié)果 用常規(guī)的雙質(zhì)粒共轉(zhuǎn)染方法能制備高產(chǎn)量的rAAV(107~108感染單位/10 cm板); 當(dāng)病毒感染多重性(MOI)=100時,rAAV/EGFP對肝癌細(xì)胞HepG2的轉(zhuǎn)染效率可達(dá)100%。
結(jié)論 重組腺病毒相關(guān)病毒可有效地轉(zhuǎn)導(dǎo)外源基因至肝癌細(xì)胞,其作為肝癌的基因治療載體具有較好的研究前景。
引用本文: 劉自明,嚴(yán)律南,王忠,林琦遠(yuǎn). 重組腺病毒相關(guān)病毒作為肝癌基因治療載體的初步研究. 中國普外基礎(chǔ)與臨床雜志, 2001, 8(3): 133-134. doi: 復(fù)制
1. | Koeberl DD, Alxander IE, Halbert CL, et al. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adenoassociated virus vector 〔J〕. Proc Natl Acad Sci USA, 1997; 94(4)∶1426. |
2. | Xiao X, Juan L, Samulski RJ. Efficient longterm gene transfer into muscle tissue of immunocompetent mice by adenoassociated virus vector 〔J〕. J Virology, 1996; 70(11)∶8098. |
3. | Maass G, Bogedain C, Scheer U, et al. Recombinant adenoassociated virus for the generation of autologous, genemodified tumor vaccine:evidence for a high transduction efficiency into primary epithelial cancer cells 〔J〕. Human Gene Therapy, 1998; 9(7)∶1049. |
4. | Flotte TR, Carter BJ. Adenoassociated virus vectors for gene therapy 〔J〕. Gene therapy, 1995; 2(6)∶357. |
- 1. Koeberl DD, Alxander IE, Halbert CL, et al. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adenoassociated virus vector 〔J〕. Proc Natl Acad Sci USA, 1997; 94(4)∶1426.
- 2. Xiao X, Juan L, Samulski RJ. Efficient longterm gene transfer into muscle tissue of immunocompetent mice by adenoassociated virus vector 〔J〕. J Virology, 1996; 70(11)∶8098.
- 3. Maass G, Bogedain C, Scheer U, et al. Recombinant adenoassociated virus for the generation of autologous, genemodified tumor vaccine:evidence for a high transduction efficiency into primary epithelial cancer cells 〔J〕. Human Gene Therapy, 1998; 9(7)∶1049.
- 4. Flotte TR, Carter BJ. Adenoassociated virus vectors for gene therapy 〔J〕. Gene therapy, 1995; 2(6)∶357.